Meningitis - a possible new treatment
This research was completed on 30 April 2003
|Project Leader||Dr Nigel J Klein, PhD, Professor Malcolm W Turner, DSc (Med) and Dr Robert C Read, FRCP|
|Location||Immunobiology Unit, Institute of Child Health, University College London Medical School in conjunction with the Department of Medical Microbiology, University of Sheffield Medical School.|
|Grant awarded||13 March 2000|
|Start date||1 May 2000|
|End date||30 April 2003|
We do not provide medical advice. If you would like more information about a condition or would like to talk to someone about your health, contact NHS Choices or speak to your GP. Please see our useful links page for some links to health information, organisations we are working with and other useful organisations. We hope you will find these useful. We are not responsible for the content of any of these sites.Meningitis affects about 3000 people every year in the UK and in those patients presenting with severe shock, the death rate may be as high as 50%. Although meningitis can occur at any age, it mainly affects babies and younger children who have less natural immunity. Recent studies have indicated that a protein, mannose binding lectin (MBL) is important in our natural defence against Neisseria meningitidis, a bacterium which causes meningitis and septicaemia. This proposal aims to explore the mechanisms by which this protein may control our defence against these bacteria. This should provide considerable insight into the role of MBL in meningitis and establish a rationale for its use as a method of treatment.